Immunovia to discuss adoption of IMMrayTM PanCan-d with key opinion leaders on May 3, 2023 - Marketscreener.com
| IMMNOV Stock | SEK 0.85 0.20 30.77% |
About 55% of Immunovia Publ's investors are presently thinking to get in. The analysis of current outlook of investing in Immunovia publ AB suggests that some traders are interested regarding Immunovia Publ's prospects. The current market sentiment, together with Immunovia Publ's historical and current headlines, can help investors time the market. In addition, many technical investors use Immunovia publ AB stock news signals to limit their universe of possible portfolio assets.
Immunovia |
Immunovia to discuss adoption of IMMrayTM PanCan-d with key opinion leaders on May 3, 2023 Marketscreener.com
Read at news.google.com
 |
Immunovia Publ Fundamental Analysis
We analyze Immunovia Publ's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovia Publ using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovia Publ based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Immunovia Publ is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Immunovia publ AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunovia Publ stock to make a market-neutral strategy. Peer analysis of Immunovia Publ could also be used in its relative valuation, which is a method of valuing Immunovia Publ by comparing valuation metrics with similar companies.
Peers
Immunovia Publ Related Equities
| ADDV-B | ADDvise Group | 5.29 | ||||
| ADVE | Advenica | 1.02 | ||||
| AWRD | Awardit AB | 0.38 | ||||
| HANZA | Hanza AB | 1.11 | ||||
| DOXA | Doxa AB | 26.67 |
Complementary Tools for Immunovia Stock analysis
When running Immunovia Publ's price analysis, check to measure Immunovia Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia Publ is operating at the current time. Most of Immunovia Publ's value examination focuses on studying past and present price action to predict the probability of Immunovia Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia Publ's price. Additionally, you may evaluate how the addition of Immunovia Publ to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |